Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
Ian MitchellAbby LiCandice L BjornsonKrista L LanctotBosco A Paesnull nullPublished in: American journal of perinatology (2021)
· Main indications were prematurity (63.3%); "miscellaneous" (17.8%); hemodynamically significant congenital heart disease (10.5%); bronchopulmonary dysplasia/chronic lung disease (8.4%).. · The proportion of children in the "miscellaneous" group, comprised of those with trisomy 21, airway anomalies, pulmonary disorders, cystic fibrosis, neurological impairments, immunocompromised, cardiac aged >2 years, multiple conditions, and a residual "unclassified" group, increased over time (4.4% in 2005-2006 to 22.5% in 2016-2017).. · Respiratory illness-related hospitalization occurred in 2,054 children (6.9%); 198 (9.6%) required intubation. Three hundred thirty-seven hospitalized children were RSV-positive (overall RSVH: 1.6%)..
Keyphrases
- respiratory syncytial virus
- congenital heart disease
- cystic fibrosis
- young adults
- preterm infants
- cardiac arrest
- heart failure
- pulmonary hypertension
- metabolic syndrome
- lung function
- chronic obstructive pulmonary disease
- skeletal muscle
- air pollution
- low birth weight
- extracorporeal membrane oxygenation
- preterm birth